title: Developmental toxicity of the angiotensin II type 1 receptor antagonists during human pregnancy: a report of 10 cases.
abstract: OBJECTIVE
  Angiotensin II type 1 receptor antagonists (ARA). Interacted with the renin-angiotensin system, and the present study was undertaken to examine their fetal and neonatal toxicity when taken by the mother during pregnancy.
  
  
  METHODS
  Prospective follow up of pregnant women exposed to an ARA during early pregnancy.
  
  
  METHODS
  The present study was conducted in the departments of Paedriatric Pharmacology of the University hospital Robert Debre in Paris, France.
  
  
  METHODS
  Ten women exposed to an ARA during early pregnancy.
  
  
  METHODS
  Prospective follow up.
  
  
  METHODS
  Fetal ultrasonography and outcome of pregnancy.
  
  
  RESULTS
  Prenatal ultrasonography showed abnormal features in five cases (oligoamnios related to fetal tabular dysgenesis, fetal dysmorphia and renal abnormalities). Outcome of pregnancy was as follows: three induced abortions, two stillbirths (twin pregnancy), one neonate presenting with dysmorphia and renal disease and five neonates with an uneventful development.
  
  
  CONCLUSIONS
  Women of reproductive age should be advised of the possible hazards of ARA and treatment should be stopped as soon as pregnany has been documented.
authors.affiliation: Department of Pediatric Pharmacology and Pharmacogenetics, Hôpital Robert Debré, Paris, France.
authors.forename: Raphael
authors.initials: R
authors.lastname: Serreau
authors.forename: Dominique
authors.initials: D
authors.lastname: Luton
authors.forename: Marie-Alice
authors.initials: MA
authors.lastname: Macher
authors.forename: Anne-Lise
authors.initials: AL
authors.lastname: Delezoide
authors.forename: Catherine
authors.initials: C
authors.lastname: Garel
authors.forename: Evelyne
authors.initials: E
authors.lastname: Jacqz-Aigrain
mesh_terms: D000014:Abnormalities, Drug-Induced / Q000000981:diagnostic imaging / Q000209:etiology*; D000328:Adult; D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D000075202:Contraindications; D005260:Female; D005333:Fetus / Q000002:abnormalities*; D005500:Follow-Up Studies; D006801:Humans; D046110:Hypertension, Pregnancy-Induced / Q000188:drug therapy*; D011247:Pregnancy; D011446:Prospective Studies; D012084:Renin-Angiotensin System / Q000187:drug effects; D013723:Teratogens / Q000633:toxicity*; D016216:Ultrasonography, Prenatal
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D013723:Teratogens